|
|
 |
|
Total Number of Holdings (excluding cash): 50
| Eli Lilly and Company |
LLY |
532457108 |
Pharmaceuticals |
2,475 |
$2,442,948.75 |
7.07% |
| Merck & Co., Inc. |
MRK |
58933Y105 |
Pharmaceuticals |
21,021 |
$2,387,144.76 |
6.91% |
| Bristol-Myers Squibb Company |
BMY |
110122108 |
Pharmaceuticals |
41,733 |
$2,361,670.47 |
6.84% |
| Johnson & Johnson |
JNJ |
478160104 |
Pharmaceuticals |
10,477 |
$2,353,343.74 |
6.81% |
| AbbVie Inc. |
ABBV |
00287Y109 |
Pharmaceuticals |
11,216 |
$2,299,616.48 |
6.66% |
| Viatris Inc. |
VTRS |
92556V106 |
Pharmaceuticals |
87,169 |
$1,390,345.55 |
4.02% |
| Biogen Inc. |
BIIB |
09062X103 |
Biotechnology |
6,784 |
$1,293,573.12 |
3.74% |
| Pfizer Inc. |
PFE |
717081103 |
Pharmaceuticals |
47,068 |
$1,248,714.04 |
3.61% |
| Regeneron Pharmaceuticals, Inc. |
REGN |
75886F107 |
Biotechnology |
1,665 |
$1,200,548.25 |
3.48% |
| Gilead Sciences, Inc. |
GILD |
375558103 |
Pharmaceuticals |
8,738 |
$1,190,989.40 |
3.45% |
| United Therapeutics Corporation |
UTHR |
91307C102 |
Pharmaceuticals |
1,920 |
$1,145,779.20 |
3.32% |
| Vertex Pharmaceuticals Incorporated |
VRTX |
92532F100 |
Pharmaceuticals |
2,620 |
$1,120,443.00 |
3.24% |
| Amgen Inc. |
AMGN |
031162100 |
Pharmaceuticals |
3,353 |
$1,110,211.83 |
3.21% |
| Zoetis Inc. |
ZTS |
98978V103 |
Pharmaceuticals |
9,927 |
$1,104,080.94 |
3.20% |
| Cardinal Health, Inc. |
CAH |
14149Y108 |
Pharmaceuticals |
5,678 |
$1,087,280.22 |
3.15% |
| Jazz Pharmaceuticals Plc |
JAZZ |
G50871105 |
Pharmaceuticals |
3,943 |
$901,251.51 |
2.61% |
| Incyte Corporation |
INCY |
45337C102 |
Biotechnology |
8,062 |
$804,990.70 |
2.33% |
| Illumina, Inc. |
ILMN |
452327109 |
Biotechnology |
4,308 |
$614,234.64 |
1.78% |
| Exelixis, Inc. |
EXEL |
30161Q104 |
Biotechnology |
12,111 |
$589,805.70 |
1.71% |
| Charles River Laboratories International, Inc. |
CRL |
159864107 |
Biotechnology |
2,505 |
$455,233.65 |
1.32% |
| Neurocrine Biosciences, Inc. |
NBIX |
64125C109 |
Biotechnology |
3,099 |
$455,614.98 |
1.32% |
| Medpace Holdings, Inc. |
MEDP |
58506Q109 |
Biotechnology |
1,019 |
$434,899.01 |
1.26% |
| PTC Therapeutics, Inc. |
PTCT |
69366J200 |
Biotechnology |
6,420 |
$427,379.40 |
1.24% |
| BioMarin Pharmaceutical Inc. |
BMRN |
09061G101 |
Pharmaceuticals |
7,443 |
$406,387.80 |
1.18% |
| Halozyme Therapeutics, Inc. |
HALO |
40637H109 |
Biotechnology |
5,896 |
$391,199.60 |
1.13% |
| Alkermes Plc |
ALKS |
G01767105 |
Pharmaceuticals |
9,873 |
$348,714.36 |
1.01% |
| Elanco Animal Health Incorporated |
ELAN |
28414H103 |
Pharmaceuticals |
12,871 |
$336,962.78 |
0.98% |
| Spyre Therapeutics, Inc. |
SYRE |
00773J202 |
Biotechnology |
4,162 |
$303,826.00 |
0.88% |
| Travere Therapeutics, Inc. |
TVTX |
89422G107 |
Pharmaceuticals |
6,008 |
$268,918.08 |
0.78% |
| TG Therapeutics, Inc. |
TGTX |
88322Q108 |
Biotechnology |
5,948 |
$249,637.56 |
0.72% |
| Arrowhead Pharmaceuticals, Inc. |
ARWR |
04280A100 |
Biotechnology |
3,076 |
$243,434.64 |
0.70% |
| Catalyst Pharmaceuticals, Inc. |
CPRX |
14888U101 |
Biotechnology |
7,756 |
$236,713.12 |
0.69% |
| Arcus Biosciences, Inc. |
RCUS |
03969F109 |
Biotechnology |
8,787 |
$228,462.00 |
0.66% |
| Twist Bioscience Corporation |
TWST |
90184D100 |
Biotechnology |
3,815 |
$227,106.95 |
0.66% |
| Mirum Pharmaceuticals, Inc. |
MIRM |
604749101 |
Biotechnology |
1,940 |
$213,555.20 |
0.62% |
| Ligand Pharmaceuticals Inc. (Class B) |
LGND |
53220K504 |
Biotechnology |
902 |
$209,760.10 |
0.61% |
| Amneal Pharmaceuticals, Inc. |
AMRX |
03168L105 |
Pharmaceuticals |
15,297 |
$208,345.14 |
0.60% |
| Protagonist Therapeutics, Inc. |
PTGX |
74366E102 |
Biotechnology |
1,944 |
$202,117.68 |
0.59% |
| Krystal Biotech, Inc. |
KRYS |
501147102 |
Biotechnology |
649 |
$187,554.51 |
0.54% |
| Roivant Sciences Ltd. |
ROIV |
G76279101 |
Biotechnology |
6,185 |
$178,251.70 |
0.52% |
| 10X Genomics, Inc. (Class A) |
TXG |
88025U109 |
Biotechnology |
7,765 |
$176,576.10 |
0.51% |
| Guardant Health, Inc. |
GH |
40131M109 |
Biotechnology |
1,906 |
$175,828.50 |
0.51% |
| Ionis Pharmaceuticals, Inc. |
IONS |
462222100 |
Pharmaceuticals |
2,205 |
$169,454.25 |
0.49% |
| Kymera Therapeutics, Inc. |
KYMR |
501575104 |
Biotechnology |
1,960 |
$169,069.60 |
0.49% |
| Supernus Pharmaceuticals, Inc. |
SUPN |
868459108 |
Pharmaceuticals |
3,271 |
$168,292.95 |
0.49% |
| Alnylam Pharmaceuticals, Inc. |
ALNY |
02043Q107 |
Biotechnology |
538 |
$163,014.00 |
0.47% |
| Moderna, Inc. |
MRNA |
60770K107 |
Biotechnology |
3,341 |
$163,007.39 |
0.47% |
| Arcutis Biotherapeutics, Inc. |
ARQT |
03969K108 |
Biotechnology |
6,637 |
$160,416.29 |
0.46% |
| ACADIA Pharmaceuticals Inc. |
ACAD |
004225108 |
Biotechnology |
7,288 |
$156,546.24 |
0.45% |
| Tarsus Pharmaceuticals, Inc. |
TARS |
87650L103 |
Biotechnology |
2,371 |
$153,545.96 |
0.44% |
| US Dollar |
$USD |
|
Other |
29,205 |
$29,204.94 |
0.08% |
Holdings are subject to change.
The holdings information set forth above for the date indicated reflects creation and redemption transactions from the prior business day and may differ from the holdings information currently available from the Fund's custodian and accounting agent. With respect to the market value of the Fund's holdings set forth above, the pricing sources are generally third party vendors. The Fund ultimately relies on pricing information provided by the Fund's accounting agent.
|
|
The information presented is not intended to constitute an investment recommendation for, or advice to, any specific person. By providing this information, First Trust is not undertaking to give advice in any fiduciary capacity within the meaning of ERISA, the Internal Revenue Code or any other regulatory framework. Financial professionals are responsible for evaluating investment risks independently and for exercising independent judgment in determining whether investments are appropriate for their clients.
|